Repare Therapeutics Inc. (RPTX)
| Previous Close | 3.4500 |
| Open | 3.4500 |
| Bid | 3.3800 x 200 |
| Ask | 3.4600 x 100 |
| Day's Range | 3.3900 - 3.5900 |
| 52 Week Range | 2.9800 - 13.8500 |
| Volume | |
| Avg. Volume | 126,971 |
| Market Cap | 144.314M |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2300 |
| Earnings Date | Feb 26, 2024 - Mar 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.33 |
- Business Wire
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
MONTREAL & LAUSANNE, Switzerland, April 30, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC (NCT04855656) clinical trial investigating lun
Business WireDebiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
LAUSANNE, Switzerland & MONTREAL, April 30, 2024--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, and Repare Therapeutics Inc. ("Repare") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC (NCT04855656) clinical trial, investigating the combination of Debio
- Business Wire
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
CAMBRIDGE, Mass. & MONTREAL, April 26, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term a
